Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm|Pancreatic Neoplasm|Lung Neoplasm|Ovarian Neoplasm|Renal Neoplasm
Interventions: DRUG: TAK-165
Sponsor: Takeda